Concord Drugs Ltd - 538965 - Audited Financial Results For The Quarter And Year Ended 31.03.2021
Audited financial results for the quarter and year ended 31.03.202128-06-2021
28-06-2021
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Audited Results For The Period Ended 31.03.2021
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/06/2021 ,inter alia, to consider and approve Audited results for the period ended 31.03.202116-06-2021
Concord Drugs Ltd - 538965 - Compliance Certificate For The Half Year Ended 31.03.2021
Compliance certificate for the half year ended 31.03.202129-04-2021
Concord Drugs Ltd - 538965 - PCS Certificate For Transfer/Transmission/Transposition
PCS Certificate for Transfer/Transmission/Transposition29-04-2021
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate u/r 74(5) of SEBI (DP) Regulations, 201829-04-2021
Concord Drugs Ltd - 538965 - Shareholding for the Period Ended March 31, 2021
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here20-04-2021
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer20-04-2021
Concord Drugs Ltd - 538965 - Announcement Under Regulation 30 Of SEBI (LODR) Regulations
Starting of Dry Syrup Division06-04-2021
Concord Drugs Ltd - 538965 - Closure of Trading Window
Closure of trading window for the quarter ended 31.03.202131-03-2021